Share on LinkedInShare on LinkedIn

ARTICLE · 28 JANUARY 2020

Aurinia Pharmaceuticals Inc. Completes US$191.7 Million Public Offering

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

On December 12, 2019, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (Aurinia or the Company) announced the closing of its previously announced underwritten ...

CanadaCorporate/Commercial Law

Date closed: 12/12/2019

Value: US$191.7 million

On December 12, 2019, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (Aurinia or the Company) announced the closing of its previously announced underwritten public offering of 12,782,439 common shares, including 1,667,274 common shares pursuant to the full exercise of the underwriters' option to purchase additional common shares (the Offering). The shares were sold at a public offering price of US$15.00 per share. The gross offering proceeds to the Company from this Offering are approximately US$191.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Jefferies LLC and SVB Leerink LLC acted as joint book-running managers for the Offering. H.C. Wainwright & Co. LLC, Oppenheimer & Co. Inc., and Bloom Burton Securities Inc. acted as co-managers for the Offering.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from